Copyright
©The Author(s) 2020.
World J Gastroenterol. Jan 14, 2020; 26(2): 168-183
Published online Jan 14, 2020. doi: 10.3748/wjg.v26.i2.168
Published online Jan 14, 2020. doi: 10.3748/wjg.v26.i2.168
Table 5 Factors that predict relapsed hepatitis C virus patients (n = 30) from SOF + SIM therapy (n = 30) using logistic regression analysis
Parameter | B | SE | P value | Odds ratio | Odds ratio (95%CI) |
Univariate analysis | |||||
LncRNA-Gas5 | 2.35 | 0.564 | < 0.001b | 10.48 | 3.47-31.67 |
LncRNA-BISPR | 2.27 | 0.555 | < 0.001b | 9.69 | 3.26-28.73 |
LncRNA-HEIH | 1.99 | 0.599 | 0.001b | 7.31 | 2.26-23.63 |
mRNA BST2 | -3.15 | 0.858 | < 0.001b | 0.042 | 0.08-0.228 |
ALT (IU/L) | 0.87 | 0.037 | 0.01a | 1.09 | 1.01-1.17 |
ALP (IU/L) | 0.069 | 0.022 | 0.002b | 1.07 | 1.02-1.11 |
Multivariate analysis | |||||
LncRNA-Gas5 | 1.46 | 0.69 | 0.03a | 4.322 | 1.12-16.70 |
LncRNA-HEIH | 1.4 | 0.714 | 0.04a | 8.885 | 1.00-16.51 |
- Citation: El Samaloty NM, Shabayek MI, Ghait RS, El-Maraghy SA, Rizk SM, El-Sawalhi MM. Assessment of lncRNA GAS5, lncRNA HEIH, lncRNA BISPR and its mRNA BST2 as serum innovative non-invasive biomarkers: Recent insights into Egyptian patients with hepatitis C virus type 4. World J Gastroenterol 2020; 26(2): 168-183
- URL: https://www.wjgnet.com/1007-9327/full/v26/i2/168.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i2.168